Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

NCT05559450 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab
OTHER: Conventional therapy

Sponsor

The First Affiliated Hospital of Soochow University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]